Tonix Pharmaceuticals announced that during a virtual event co-hosted by BIO and Solve M.E. titled, "Long COVID: What Will it Take to Accelerate Therapeutic Progress?", Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, presented emerging research describing the role of infections in triggering fibromyalgia or CFS/ME and other fibromyalgia-type illnesses, and discussed Tonix’s ongoing Phase 2 study of TNX-102 SL in fibromyalgia-type Long COVID. "The U.S. Department of Health and Human Services National Research Action Plan on Long COVID1, released in August 2022, addresses the overlap of Long COVID with CFS/ME, which, like fibromyalgia, is one of the overlapping chronic pain syndromes with central sensitization," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Furthermore, a recent survey found comparable pain, fatigue and function between Long COVID, fibromyalgia and CFS/ME."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNXP:
- Tonix Pharmaceuticals to participate in event on Long COVID
- Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
- Tonix Pharmaceuticals annunces exclusive license of Anti-SARS-CoV-2 mAbs
- Tonix Pharmaceuticals announces paper highlighting development of TNX-801
- Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)
